B-Type Natriuretic Peptide and Echocardiography in the Surveillance of Severe Mitral Regurgitation Prior to Valve Surgery⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by McCullough, Peter A. & Hanzel, George S.
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eorge S. Hanzel, MD‡
oyal Oak, Michigan
rimary mitral regurgitation (MR) should be a recognizable
recursor to left ventricular (LV) failure and death. The
hallenge for practicing clinicians is to identify the disease
rocess and provide a surveillance program that will allow
he detection of a change in status sensed by the left
entricle and left atrium heralding decompensation in the
onths and years that follow. Such a surveillance program
ould allow for avoidance of surgery in those patients who
re stable and optimal timing of valve surgery prior to
rreversible cardiac structural changes or the occurrence of
ny clinical consequence, including atrial fibrillation, the
evelopment of heart failure, or cardiac death. Traditionally,
See page 1099
his surveillance approach has been grounded in the clinical
xamination and echocardiography. The American College
f Cardiology/American Heart Association (ACC/AHA)
uidelines advise that asymptomatic patients with severe
R should be followed up with a history, physical exami-
ation, and echocardiography every 6 to 12 months to assess
ymptoms or transition to asymptomatic LV dysfunction
1). Exercise stress testing may be used to add objective
vidence of a change in physiologic consequences of severe
R (1). The ACC/AHA guidelines and the European
ociety of Cardiology (ESC) guidelines recommend mitral
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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edicine, and the ‡Department of Cardiology, William Beaumont Hospital, Royalt
ak, Michigan. Dr. Hanzel served as a proctor for the Helex PFO/ASD Closure
evice for W. L. Gore.alve surgery in asymptomatic patients with LV systolic
ysfunction or enlargement, pulmonary hypertension, or
ew-onset atrial fibrillation (1,2). Additionally, the
CC/AHA guidelines suggest early surgery in the ab-
ence of these findings if mitral valve repair rate is
stimated to be 90% (Class IIa) (1). This last recom-
endation is controversial and is not addressed in the
SC guidelines. Two studies suggest reduced cardiac
vents, including death, with early surgical intervention
n asymptomatic patients with severe MR (3,4). How-
ver, a third study reports no difference in mortality in
atients treated with early surgery compared with those
ho undergo surgery only with the development of
ymptoms, LV dysfunction or enlargement, atrial fibril-
ation, or pulmonary hypertension (5). These divergent
tudies confound clinical decision-making, particularly
ince the mitral valve repair rate is only 50% in the U.S.
6). Thus, it is desirable to develop novel predictors of
ecompensation to efficiently target the optimal patient
or early surgery.
In this issue of the Journal, Pizarro et al. (7) report on
he addition of baseline blood B-type natriuretic peptide
BNP) in the clinical assessment of patients with asymp-
omatic severe MR. We anticipate that both atrial and
entricular cardiomyocytes produce BNP primarily in
esponse to end-diastolic wall stress as shown in Figure 1
8,9). Importantly, data were prospectively collected,
linded, and then split into derivation and validation sets
or analysis. Baseline BNP 105 pg/ml (highest quar-
ile), just above the approved normal cutpoint of 100
g/ml, and a more prominent change in BNP at 1 year
25 pg/ml increase for those with BNP 105 pg/ml),
redicted the composite outcome of a clinical conse-
uence of severe MR. Baseline BNP 105 pg/ml iden-
ified a subset of patients at high risk for developing
ymptoms, LV systolic dysfunction, or death at 48
onths (derivation set: 76% vs. 5.4%, p  0.001, and
alidation set: 66% vs. 4%, p  0.001). Importantly,
ptimal timing of surgery occurred before any clinical
vents in only 25 of 76 patients (33%). This implies that
mproved surveillance with BNP could have potentially
llowed for better timing of surgery in up to two-thirds of
ases with the avoidance of complications, including
ospitalizations for heart failure, arrhythmias, and death.
iven the observation that up to 90% of patients with
evere MR, especially with those that develop a flail
eaflet, will die untreated in 10 years, one could make the
ase that more frequent surveillance (every 3 or 6 months)
ith a readily available, inexpensive blood test could
omplement annual or semiannual echocardiographic
ssessments. Conversely, 2 other studies suggest mortal-
ty rates of 10% at 7 to 8 years in patients monitored by
watchful waiting,” implying that with the right clinical
ssessment, a group appropriate for prolonged observa-
ion can be identified.
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B-Type Natriuretic Peptide September 15, 2009:1107–9The key messages from this paper are that baseline
NP 105 pg/ml, very severe mitral regurgitation (ef-
ective regurgitant orifice area [EROA] 55 mm2), and
V dilation (end-systolic diameter indexed to body
urface area 22 mm/m2) all had significant, indepen-
ent odds ratios (range 3.4 to 4.6) for the combined end
oint. Other studies have found that BNP, as a reflection
f wall tension and myocardial performance, is relatively
ndependent of MR severity, jet size, or regurgitant fraction
10–12). This intimates that in an asymptomatic patient
ith severe MR and a normal ejection fraction, any 1 of
hese 3 findings (elevation of BNP, worsening EROA
eyond 40 mm2, LV dilation) should raise a red flag for a
omplication over the next 2 to 3 years and potentially
hould prompt referral for mitral valve surgery despite good
xercise tolerance (9 metabolic equivalents of work) (4).
We anticipate that future research will guide the frequency
f BNP measurement needed and clarify the changes within
he normal range that signal LV decompensation in the
onths to come. It appears that a change in BNP is probably
he first clinical signal, prior to any measure on echocardiog-
aphy or the development of symptoms, that can inform both
he physician and the patient of trouble ahead as a consequence
f severe MR (12). In these patients, it is expected that mitral
alve surgery offers the opportunity for a reduction in clinical
Figure 1 BNP Release
Pathophysiology of B-type natriuretic peptide (BNP) release in the setting of mitral
ventricular increases in wall tension are expected to trigger the up-regulation of thvents, including mortality.eprint requests and correspondence: Dr. Peter A. McCullough,
ivision of Nutrition and Preventive Medicine, William Beaumont
ospital, 4949 Coolidge, Royal Oak, Michigan 48073. E-mail:
eteramccullough@gmail.com.
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